Ls 2x Salesforc News - CRME

K I L L K I L L K I L L -- Cardiome Pharma Corp.

VANCOUVER, June 3 /PRNewswire-FirstCall/ -- Editors are advised to disregard TO249, "TEST - Jay 14 - Cardiome Announces Positive Interim Phase...

TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic

NASDAQ: CRME TSX: COM VANCOUVER, May 28 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRME/TSX:NASDAQ:COM) today announced positive...

Cardiome Reports First Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, May 13 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome To Release 2008 First Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, May 12 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome Reports 2007 Results

NASDAQ: CRME TSX: COM VANCOUVER, March 26 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ:CRME/TSX:NASDAQ:COM) today reported financial...

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fib

DEERFIELD, Ill. and VANCOUVER, British Columbia, March 25 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. and its co-development partner...

Cardiome To Release 2007 Results

NASDAQ: CRME TSX: COM VANCOUVER, March 24 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ:CRME/TSX:NASDAQ:COM) today announced that it...

Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor

NASDAQ: CRME TSX: COM VANCOUVER, March 17 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ:CRME/TSX:NASDAQ:COM) today announced positive...

Cardiome to Hold Investor Update Call

NASDAQ: CRME TSX: COM VANCOUVER, Dec. 14 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRME/TSX:NASDAQ:COM) today announced that a...

FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation

VANCOUVER, British Columbia and DEERFIELD, Ill., Dec. 11 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (Nasdaq: CRME; TSX: COM) and its...

Cardiome Updates Guidance

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome Initiates Phase 1 Study for GED-aPC

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 20 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRME/TSX:NASDAQ:COM) today announced...

Cardiome Reports Third Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 13 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome To Release Third Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ls 2x Salesforc (CRME)

Professional-Grade Tools, for Individual Investors.

CRME News

K I L L K I L L K I L L -- Cardiome Pharma Corp.

TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic

Cardiome Reports First Quarter Results

Cardiome To Release 2008 First Quarter Results

Cardiome Reports 2007 Results

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fib

Cardiome To Release 2007 Results

Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor

Cardiome to Hold Investor Update Call

FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation

Cardiome Updates Guidance

Cardiome Initiates Phase 1 Study for GED-aPC

Cardiome Reports Third Quarter Results

Cardiome To Release Third Quarter Results

CRME Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ls 2x Salesforc (CRME) News

Ls 2x Salesforc (CRME)

Professional-Grade Tools, for Individual Investors.

CRME News

K I L L K I L L K I L L -- Cardiome Pharma Corp.

TEST - Jay 14 - Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic

Cardiome Reports First Quarter Results

Cardiome To Release 2008 First Quarter Results

Cardiome Reports 2007 Results

Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fib

Cardiome To Release 2007 Results

Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor

Cardiome to Hold Investor Update Call

FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation

Cardiome Updates Guidance

Cardiome Initiates Phase 1 Study for GED-aPC

Cardiome Reports Third Quarter Results

Cardiome To Release Third Quarter Results

CRME Discussion

Your Recent History